ALK

(redirected from ALKS)
Also found in: Acronyms.

ALK

Abbreviation for:
activin-like kinase
anaplastic lymphoma kinase, see there

Genetics
A gene on 2p23 that encodes an orphan receptor with tyrosine kinase activity belonging to the insulin receptor superfamily, which plays an important role in brain development.

Molecular pathology
ALK is amplified, mutated and rearranged in various cancers, including anaplastic large cell lymphomas, neuroblastoma and non-small cell lung cancer. The most common genetic alterations seen in ALK malfunction are chromosomal rearrangements resulting in multiple fusion genes, including ALK/EML4, ALK/RANBP2 and ALK/ATIC (all on chromosome 2); ALK/TFG (on chromosome 3); ALK/NPM1 and ALK/SQSTM1 (both on chromosome 5); ALK/KIF5B (on chromosome 10); ALK/CLTC (on chromosome 17); ALK/TPM4 (on chromosome 19); and ALK/MSN (on X chromosome).
References in periodicals archive ?
In June 2011, Alkermes announced data from a phase 1b double-blind, randomized, placebo-controlled clinical study of ALKS 9070 in 32 patients with schizophrenia.
Subsequently, a drug-drug interaction study was performed to identify the ALKS 33 and buprenorphine ratio that would provide complete blockade.
The multicenter, randomized, double-blind, placebo- and active-controlled study was designed to compare the mean change from baseline in body weight in 106 healthy volunteers following three weeks of once-daily, oral administration of ALKS 3831, compared to olanzapine alone or placebo.
In an initial clinical trial, ALKS 33 at 10-mg and 20-mg oral doses completely blocked the effects of serial pulses of remifentanil in opioid-experienced volunteers.
Results from the 12-week study revealed ALKS 33 was not more effective than placebo in reducing weekly episodes of binge eating.
A second phase 2b study of ALKS 37 for the treatment of opioid-induced constipation is concluding, and no additional clinical studies for ALKS 37 are planned.
We are delighted to present these results to experts in the mental health community at the NCDEU meeting showing that ALKS 5461 offers potential as a novel treatment for patients with MDD who have inadequate response to antidepressant therapy.
The rapid onset of effect observed in patients treated with ALKS 5461 in this study is very encouraging.
The phase 2, randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 in 68 patients with binge eating disorder.
The study was a randomized, multicenter, double-blind, placebo-controlled, 20-week study that assessed the safety, tolerability and pharmacokinetics of a single administration of three ascending doses of ALKS 9070 in 32 patients with chronic, stable schizophrenia.
The phase 1/2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, multi-dose study is designed to evaluate the safety and tolerability of ALKS 5461 in 32 patients with major depressive disorder who had shown an inadequate response to previous antidepressant therapy.
The phase 2, multi-center, randomized, double-blind, placebo-controlled, multi-dose study of ALKS 37 was designed to evaluate the efficacy, safety and tolerability of escalating doses of ALKS 37 in 87 patients experiencing OIC during treatment with opioids for chronic, non-cancer pain.